Hodgkin's disease (lymphoma) diagnosis starts with a physical exam for swollen lymph nodes, followed by a lymph node biopsy, which is the definitive test to identify the cancer cells (Reed-Sternberg cells) under a microscope. If lymphoma is confirmed, imaging (CT, PET, MRI scans) and blood tests (checking organ function, LDH levels) are done to determine if the cancer has spread (staging). A bone marrow biopsy may also be performed.
In some instances, the DNA mutation that leads to Hodgkin lymphoma is caused by the Epstein-Barr virus (EBV), a common and highly contagious herpes infection spread through bodily fluids, such as saliva. Scientists believe EBV is a “transforming agent” that can cause healthy lymphocytes to become cancerous.
You're more likely to develop this condition if you're between 20 and 39 years old or older than 65. Your sex. Males are more likely to develop Hodgkin lymphoma. The exception is nodular sclerosis, a classic Hodgkin lymphoma subtype that's more common in females.
A lymph node biopsy is when your doctor removes all or part of a lymph node. This is the only way to find out for sure why a lymph node is swollen. This is the most important test in diagnosing Hodgkin lymphoma.
Stage I. Either of the following means that the Hodgkin lymphoma is stage I: Hodgkin lymphoma is found in only 1 lymph node area or lymphoid organ, such as the thymus (I). The cancer is found only in 1 part of 1 organ outside the lymph system (IE).
How patients described their first signs of lymphoma
almost 95 out of every 100 (almost 95%) survive their cancer for 1 year or more. almost 90 out of every 100 (almost 90%) survive their cancer for 5 years or more. more than 80 out of every 100 (more than 80%) survive their cancer for 10 years or more.
Most types of lymphoma can't be diagnosed by a blood test alone. However, most people affected by lymphoma will have blood tests as part of their diagnosis and frequently throughout treatment. You continue to have blood tests, though less frequently, after treatment during follow-up.
The most common early sign of lymphoma is a painless enlarged lymph node(s) in the neck or upper chest. Sometimes you can feel the swollen lymph node(s) in your armpit, stomach area or groin.
Anyone can get Hodgkin lymphoma, but you may be at higher risk if: you're in your early 20s or late 70s. you're a man. you've had the Epstein-Barr virus, which causes glandular fever.
NHL most often affects adults, but children can get it too. See Non-Hodgkin Lymphoma in Children. NHL usually starts in lymph nodes or other lymph tissue, but it can sometimes affect the skin.
While Hodgkin Lymphoma (HL) often has better overall survival rates (around 90% 5-year survival vs. NHL's ~74%) and a more predictable spread, making it highly treatable, Non-Hodgkin Lymphoma (NHL) is more common, has many aggressive subtypes, and can be harder to cure, though many slow-growing NHLs behave like chronic conditions. The "worse" type depends on the specific subtype, stage, and individual factors, as NHL encompasses over 60 types, some very aggressive and others very slow-growing.
Is Hodgkin lymphoma hereditary? Having a parent or sibling with Hodgkin lymphoma may increase the risk for developing the disease. The most significant link between family history and Hodgkin lymphoma involves those who have an identical twin with the condition.
Some cases of Hodgkin lymphoma are linked to a virus called Epstein-Barr virus (EBV). In certain people, an EBV infection can lead to the development of Reed-Sternberg cells, the cancer cells found in Hodgkin lymphoma.
For most people, treatment will get rid of the lymphoma completely. But there is a risk that it might come back and you need more treatment. If this happens, treatment may still be able to get rid of the lymphoma completely.
Some treatments, such as chemotherapy drugs or CAR-T cell therapy, used to treat other types of cancer, including other blood cancers, might increase your chance of developing lymphoma in the future. Exposure to radiation, including radiotherapy for other cancers, might also increase your risk of developing lymphoma.
The most common symptom of lymphoma is a painless swelling or lump in the neck, armpit or groin. This is caused by lymphoma cells building up in the lymph nodes, which makes them bigger.
Lymphoma can be misdiagnosed as influenza, HIV, infections, and mononucleosis, among many other diseases. However, a thorough battery of tests should rule out other illnesses. Unfortunately, sometimes doctors and other medical professionals can disregard symptoms or misinterpret test results.
The Self-Lymph Node Exam
A brief assessment is all that is needed to look for two things - A palpable nodule of some sort or tenderness in the area. Examine all of the areas in the neck, armpits, and groin. If you find a firm node or painful area in any of the locations shown in the pictures take note of it.
Diagnosis of lymphoma often begins with a physical exam. This exam checks for swollen lymph nodes in the neck, underarms and groin and an enlarged spleen or liver. Other tests and procedures include blood tests, imaging tests and taking a sample of tissue for lab testing.
Having a high white blood cell count (15,000 or higher). Having a low lymphocyte count (below 600 or less than 8% of the white blood cell count).
Children and adults can develop Hodgkin lymphoma, but it's most common in early adulthood, especially in a person's 20s. The risk of Hodgkin lymphoma rises again in late adulthood, after age 55. Overall, the average age at diagnosis is 39.
For most people with Hodgkin lymphoma, side effects from chemotherapy aren't severe and they usually go away when treatment stops. They may include: infections and fever. difficulty pooing (constipation)
The incidence mortality rate for all causes is 2 per every 100 patients per year. The OS of our cohort at 10 years from diagnosis was 76% (95% CI: 72–79) and 52% at 30 years (95% CI: 48–57).
A new standard of care for advanced Hodgkin lymphoma
Friedberg said he expects that expert guidelines for treating Hodgkin lymphoma in adults and children will be revised to recommend nivolumab–AVD as the preferred initial treatment for people with advanced disease.